- The AGA supports the use of FMT for preventing recurrent Clostridium difficile infection (CDI) but does not recommend it for inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) outside of clinical trials.
- The guidelines were developed using the Grading of Recommendations, Assessment, Development, and Evaluation framework, focusing on patient-centered outcomes and evidence synthesis.
- For immunocompetent adults with recurrent CDI, FMT can be used after standard-of-care antibiotics to prevent recurrence.
- In mildly or moderately immunocompromised adults with recurrent CDI, conventional fecal microbiota transplant is recommended.
- The use of any fecal microbiota-based therapies is advised against in severely immunocompromised adults or those undergoing cytotoxic treatment.
Keep Reading
Add A Comment